Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Engelfriet

Showing results (131-140 of 171) with videos related to

Pageof 18
Sort By:
Blood|March 1, 1983
A comparison of surface marker analysis and FAB classification in acute myeloid leukemiaH J van der Reijden, D J van Rhenen, P M Lansdorp, et al.
Tissue Antigens|November 1, 1982
HLA antigens in idiopathic thrombocytopenic purpuraF M Helmerhorst, L E Nijenhuis, G G de Lange, et al.
Schweizerische Medizinische Wochenschrift|October 2, 1976
[Immunological damage to erythrocytes]C P Engelfriet, A E von dem Borne, A Fleer, et al.
Vox Sanguinis|January 1, 1993
ISBT Working Party on Terminology for Red Cell Surface Antigens. São Paulo reportG L Daniels, J J Moulds, D J Anstee, et al.
Vox Sanguinis|May 8, 1999
Blood transfusion in premature or young infants with polyagglutination and activation of the T antigenC P Engelfriet, H W Reesink, R G Strauss, et al.
Vox Sanguinis|September 12, 2007
Donor recruitment researchD Devine, M Goldman, C P Engelfriet, et al.
Lancet (London, England)|September 17, 1988
What is the best predictor of the severity of ABO-haemolytic disease of the newborn?H A Brouwers, M A Overbeeke, I van Ertbruggen, et al.
Tissue Antigens|April 1, 1976
The search for standard HLA reagentsE Albert, E S Curtoni, J Dausset, et al.
Vox Sanguinis|August 24, 1999
The treatment of patients with autoimmune thrombocytopenia with intravenous IgG-anti-DC P Engelfriet, H W Reesink, J Bussel, et al.
Vox Sanguinis|September 2, 2000
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodiesC P Engelfriet, H W Reesink, P M Mannucci, et al.
Pageof 18

Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
Blood|March 1, 1983
A comparison of surface marker analysis and FAB classification in acute myeloid leukemiaH J van der Reijden, D J van Rhenen, P M Lansdorp, et al.
Tissue Antigens|November 1, 1982
HLA antigens in idiopathic thrombocytopenic purpuraF M Helmerhorst, L E Nijenhuis, G G de Lange, et al.
Schweizerische Medizinische Wochenschrift|October 2, 1976
[Immunological damage to erythrocytes]C P Engelfriet, A E von dem Borne, A Fleer, et al.
Vox Sanguinis|January 1, 1993
ISBT Working Party on Terminology for Red Cell Surface Antigens. São Paulo reportG L Daniels, J J Moulds, D J Anstee, et al.
Vox Sanguinis|May 8, 1999
Blood transfusion in premature or young infants with polyagglutination and activation of the T antigenC P Engelfriet, H W Reesink, R G Strauss, et al.
Vox Sanguinis|September 12, 2007
Donor recruitment researchD Devine, M Goldman, C P Engelfriet, et al.
Lancet (London, England)|September 17, 1988
What is the best predictor of the severity of ABO-haemolytic disease of the newborn?H A Brouwers, M A Overbeeke, I van Ertbruggen, et al.
Tissue Antigens|April 1, 1976
The search for standard HLA reagentsE Albert, E S Curtoni, J Dausset, et al.
Vox Sanguinis|August 24, 1999
The treatment of patients with autoimmune thrombocytopenia with intravenous IgG-anti-DC P Engelfriet, H W Reesink, J Bussel, et al.
Vox Sanguinis|September 2, 2000
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodiesC P Engelfriet, H W Reesink, P M Mannucci, et al.
Pageof 18